Gynecological egg-shaped vaginal suppositories with dibunol for treating patients for inflammatory diseases

FIELD: medicine.

SUBSTANCE: means is manufactured as capsule containing dibunol and 15% oil extraction of propolis.

EFFECT: enhanced effectiveness of treatment; prolonged regenerating and antibacterial action.

2 cl

 

The present invention relates to medicine, namely to the pharmacy, and the development of a medical ovule containing BHT, and can be used in complex treatment of inflammatory diseases of female sexual sphere (salpingoophoritis, endometritis).

Known drug with antioxidant properties and a wide range of pharmacological activity, - “10% liniment dibunola” (VFS 42-326-79) under the following proportions of ingredients: BHT - 10,0; vegetable oil to 100.0 /1/.

Described drug with reparative action, is the closest analogue of the present invention to the technical essence and the achieved result.

However, the known drug containing BHT and oil-based, has the following disadvantages. therapeutic effect of 10% liniment has prolonged action due to liquid consistency and is mainly used when plugging gynecological patients in the clinic or independently, that is some inconvenience in use.

The objective of the invention is to create a new dosed medications domestic production in the form of ovules containing BHT and oil extract of propolis, possessing regenerative and Antibes is serialnum action with a uniform release, suitable for use by patients on their own, with a pronounced and prolonged action of the drug.

The technical result - the reduction of terms of complex treatment of patients with inflammatory diseases of female reproductive organs through prolonged action, as well as the convenience and hygiene applications.

This technical result is achieved in that the means for the treatment of gynecological inflammatory diseases based on dibunola, characterized in that it further comprises an oil extract of propolis, it is made in the form of capsules, including gelatin, glycerin and purified water, weighing 2.5 g, in the following ingredients: dibunola - 0.5 g and 15% of an oil extract of propolis - 1,5,

All components that are included in ovula permitted for medical use. BHT VFS 42-457-75. Propolis is THE GOST 28886-90. Gelatin medical GF X, article 309. Glycerin FS 42-2202-84. Purified water FS 42-2619-89.

As a result of experimental studies, it was found that gelatin capsules (ovule)consisting of gelatin, glycerin and purified water, have a high bioavailability and a number of advantages: they have a beautiful appearance - smooth, oval-shaped capsules 1.8 cm in length and 1 cm in diameter; therapeutic action is their content appears within 5-10 minutes after administration; the shell is made of gelatin impermeable to volatile liquids, gas, oxygen (which is very important for the safety of legkookisljajushchihsja funds). Ovule very promising for applications in gynecology. 15% oil extract of propolis promotes better distribution dibunola. Giving the medicinal product form ovula provides convenience and hygiene applications, the storage stability. Introduction in the drug of propolis extract in the amount of 15% in combination with BHT increases antimicrobial activity, tissue regeneration, promotes the expression of analgesic, hemostatic, immunomodulating, reparative effect of the dosage form.

In addition to the manifestations of the known properties of each component of the proposed structure together strengthens their influence, because, obviously, the effect of their synergies.

Example 1. Part 1 Oulu weight 2.5 g: BHT 0.5 g; 15% oil propolis extract 1.5 g; gelatin 0.5 g; glycerol, 1.0 g; distilled water to 1.0.

In beaker pre-soaked gelatin in the calculated amount of water (60-90 minutes), melted in a water bath at a temperature of not more than 70°add the glycerin. To remove air without mixing incubated for 30 minutes at a temperature of 45°after poured into a porcelain crucible. The metal is ical form (olive) is wiped with a gauze pad, soaked in vaseline oil, is cooled in a refrigerator at a temperature of 3-5°C for 5-6 minutes and immersed in a gelatinous mass at a temperature of 38-40°for 1-2 seconds. Forms gradually raise, rotating in a horizontal position around its axis and placed in the fridge for 7-10 minutes, after which the capsules carefully make an incision with a scalpel or razor blade at the base of the olive. The quality of the capsules judged by appearance, removal from olive and the integrity of the shell. Further filled with a mixture of 15% oil extract BHT, and then the remaining gelatin mixture filled capsules sealed.

Received ovule correct form, the weight is easily removed with olive, shell, elastic, soft, good filling accipiendum (BHT and 15% oil extract of propolis).

Example 2.

Part 1 Oulu weight 2.5 g: BHT 0.5 g; 15% oil propolis extract 1.5 g; gelatin 1.0 g; glycerol, 0.5 g; distilled water to 1.0.

Made of medical ovule the same way. Received ovule solid, storage crack.

Example 3.

Part 1 Oulu weight 2.5 g: BHT 0.5 g; 15% oil propolis extract 1.5 g; gelatin 0.25 g; glycerol 1,25 g; distilled water to 1.0.

Made of medical ovule the same way. Mass forms on Oliva thin, torn film, removal from olive as a whole is difficult, filling there is no way.

The given examples show that the optimal from the point of view of ease of use, effectiveness of treatment is the composition described in example 1.

Clinical trials have shown that the amount of released drug at a given ratio of components in one ovule equally in patients studied. This allows the doctor in practical medicine, depending on the form and severity of the disease to recommend patients required number of ovules for self-treatment, which makes declare ovule promising dosage form in practical gynecology. For example, studies have been conducted on the use of ovula in treatment of gynecological diseases of female genital sphere (salpingoophoritis, endometritis). You can use ovula sick yourself. After conducting a full-scale clinical trials and the development of methods for quality control ovula planned design monograph.

Sources of information taken into account:

1. VFS 42-326-79 “10% liniment dibunola”.

The treatment for gynecological inflammatory diseases based on dibunola, characterized in that it further comprises an oil extract of propolis, it is made in the form of capsules, including gelatin, glycerin and water PTS is placed a mass of 2.5 g in the following ingredients: dibunola 0.5 g and 15% of an oil extract of propolis 1,5,

2. The tool according to claim 1, characterized in that the solvent oil extract of propolis contains vegetable oil.



 

Same patents:

FIELD: veterinary science.

SUBSTANCE: the suggested preparation is a biohormonal composition consisting of gestagenic hormone 3beta-butyroxy-17alpha-acetoxy-6-methyl-pregna-4,6-diene-20-on and estrogenic hormone 17alpha-ethynyl-estratriene-1,3,5(10)-diol-3,17beta in combination with refined vegetable oil, preferably, sunflower oil; gelatin; glycerol and methyl ether of parahydroxybenzoic acid at the following ratio of ingredients, weight%: gestagenic hormone 0.50; estrogenic hormone 0.01; gelatin 14.00; glycerol 5.00; methyl ether of parahydroxybenzoic acid 0.10, vegetable oil, refined, preferably, sunflower oil - up to 100.00. The preparation provides 100% efficiency in regulating estrus both in cats and dogs.

EFFECT: higher efficiency of estrus regulation.

2 ex, 1 tbl

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

in which R1 represents H, halogen, OCH3, or OH; R2 represents (a) -X-(CH2)n-CH2-N(R4)R5, where (i) X represents NH or S; n is integer from 1 to 4; R4 and R5, the same or different, represent C1-C4-alkyl, H, -CH2C≡CH, or -CH2CH2OH; or R4 and R5, together, form nitrogen-containing five- or six-membered cycle or heteroaromatic cycle; or where (ii) X represents O; n is integer from 1 to 4; one of R4 and R5 is CH2C≡CH, or -CH2CH2OH and the other H or C1-C4-alkyl; or R4 and R5, together, form imidazole cycle or nitrogen-containing six-membered cycle or heteroaromatic cycle; or R2 represents (b) -Y-(CH2)nCH2-O-R5, where (i) Y represents O; n is integer from 1 to 4; and R6 represents -CH2CH2OH or -CH2CH2Cl; or where (ii) Y represents NH or S; n is integer from 1 to 4; and R6 represents H, -CH2CH2OH, or -CH2CH2Cl; or R2 represents (c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, or 2,2-diethyl-2-hydroxy-ethoxy; R3 represents H. halogen, OH, or -OCH3. Claimed compounds are novel selective estrogen receptor modulators. Invention also discloses pharmaceutical composition and a method for production of tissue-specific estrogenic and/or antiestrogenic effect in patient, for whom indicated effect is required.

EFFECT: increased choice of estrogen receptor modulators.

19 cl, 7 tbl, 11 ex

FIELD: veterinary medicine.

SUBSTANCE: poultry's diet during the first and second phases of egg yield should be supplemented with roxazym enzymatic complex at the ratio towards husk-bearing components being 0.007 - 0.009 : 20. The present innovation prevents inflammation of oviducal vagina in laying hens.

EFFECT: higher efficiency of prophylaxis.

3 ex

FIELD: veterinary medicine.

SUBSTANCE: poultry's diet during the first and second phases of egg yield should be supplemented with roxazym enzymatic complex at the ratio towards husk-bearing components being 0.007 - 0.009 : 20. The present innovation prevents inflammation of oviducal vagina in laying hens.

EFFECT: higher efficiency of prophylaxis.

3 ex

FIELD: medicine.

SUBSTANCE: method involves introducing cauterizing necrotizing composition like paste containing silver nitrate and dextrane into uterine cavity. Paste contact to target tissue is supported during time enough for reaching chemical necrosis. Then cauterizing composition is brought in contact with deactivating agent like aqueous solution of sodium chloride and removed from the uterine cavity later on. It is proposed to protect non-target tissue by supplying protection agent to it and carrying out previously described steps.

EFFECT: enhanced effectiveness of cauterization controlled in time and action intensity degree; avoided other tissue injuries.

30 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: method involves administering selective modulator of steroid sex hormones being in particular compounds of general formula(I) and some quantity of steroid sex hormones precursor selected from a group composed from dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-en-3β,17β-diol and compounds in vivo transformable into one of cited precursors. Bisphosphonates combined with selective estrogen receptor modulators and/or steroid sex hormones precursor are additionally introduced for medically treating and/or inhibiting osteoporosis progress.

EFFECT: enhanced effectiveness of treatment; excluded adverse side effects.

41 cl, 13 dwg, 4 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides therapeutical formulation for improving fertility and treating sterility caused by polycystic ovary syndrome, which composition is characterized by that formulation thereof involves use of dipeptidylpeptidase IV inhibitor. Treatment of polycystic ovary syndrome-caused sterility is high successful with effective active ingredient concentration equal to 1 μM. When dipeptidylpeptidase IV inhibitor is administered, luteinizing hormone and testosterone levels in blood are normalized. Claimed compounds are low toxic for warm-blooded animals and humans.

EFFECT: widened choice of efficient antisterility drugs.

7 cl, 3 ex

FIELD: medicine.

SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.

EFFECT: higher efficiency of prophylaxis.

1 cl, 1 ex, 4 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition for oral administration in treatment or prophylaxis of obesity or hyperlipidemia. The composition comprises orlistat and at least one ester of fatty acids and polyols. Melting point of fatty acid ester exceeds the body temperature and polyol is taken among group including glycerol, sugars, derivatives of sugars and their mixtures. Also, invention relates to a method for preparing above described composition and to a method for treatment or prophylaxis of obesity. Invention enhances effectiveness and activity of orlistat by reducing variability of effectiveness and/or activity of orlistat between patients and frequency and severity of adverse effects.

EFFECT: improved and valuable pharmaceutical properties of compositions.

24 cl, 1 tbl, 10 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent made as a gelatin capsule. A medicinal agent as gelatin capsule consists of cycloserine and accessory additives wherein calcium phosphate dihydrate, aerosil and calcium stearate taken in the definite components are used as accessory additives. Also, gelatin capsule comprises additionally glutamic acid, gelatin and water, Invention provides rapid and complete release of agent in intake and the development of a medicinal formulation reducing toxicity of an active substance and eliciting stability in storage.

EFFECT: improved and valuable pharmaceutical and medicinal properties of agent.

1 tbl, 1 ex

FIELD: medicine, gastroenterology, phytotherapy, pharmacy.

SUBSTANCE: invention relates to solid medicinal formulations, namely capsules "Gastrobiol-TSD". Gelatin capsule contain the natural pharmacologically active component - sea-buckthorn oil concentrate, cyclodextrin, vitamin U and magnesium oxide taken in the definite ratio of components given in the invention description. Invention provides preparing a medicinal formulation eliciting an anti-ulcer, analgetic and protective effect on mucosa effect being with minimal risk for development of adverse effect.

EFFECT: valuable medicinal properties of preparation.

1 tbl, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition as a capsule for oral administration that comprises testosterone undecanoate as an active component dissolved in pharmaceutically acceptable liquid carrier wherein liquid carrier involves at least 50 wt.-% of castor oil. Using castor oil as a liquid carrier in combination with testosterone undecanoate as androgen provides preparing a solution that can contain about 200-250 mg of testosterone undecanoate/ml that represents the new achievement for testosterone solution for oral administration. Solution can contain lipophilic surface-active substance, such as lauryl glycol also. The composition shows good absorption in human body and elicits higher activity as compared with the known composition of undecanoate.

EFFECT: improved and valuable properties of composition.

7 cl, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention discloses compositions with sustained-release of active component and masking taste that comprise one of more active components included in tricomponent matrix structure as a globule. This structure is formed successively by amphiphilic, lipophilic or inert matrices and included as globule or dispersed in hydrophilic matrix. Applying large amount of systems for regulation of dissolving active component provides modulating the dissolving rate of active component in aqueous and/or biological fluids by regulating thus kinetics in releasing active component in digestive tract.

EFFECT: valuable pharmaceutical properties of compositions.

14 cl, 14 ex

FIELD: biotechnology, veterinary medicine.

SUBSTANCE: invention relates to the development of biological preparation for prophylaxis and treatment of colibacillosis (escherichiosis) and for control of carriage of escherichious infections pathogens in animals and poultries also. Also, invention can be used in producing curative fodders and ecologically pure human foodstuffs. Biopreparation for prophylaxis and treatment of escherichiosis in animals and poultries comprises strains of bacteriophages Phagum Escherichia coli Ec022-DEP and/or Phagum Escherichia coli Ec021-DEP, and/or Phagum Escherichia coli Ex0782-DEP, and/or Phagum Escherichia coli Ec0781-DEP, and/or Phagum Escherichia coli EPZ-1-DEP, and/or Phagum Escherichia coli EPZ-2-DEP, and/or Phagum Escherichia coli EG-5-DEP, and/or Phagum Escherichia coli BC-1-DEP, and/or Phagum Escherichia coli M78-DEP, and/or Phagum Escherichia coli Sheksna 2k-DEP taken in the effective amount. The biopreparation comprises also antiseptic, for example, quinosol and a stabilizing agent. Protein (for example, soybean protein), vegetable meal, organic polymer, milk, serum, albumin can be used as a stabilizing agent. Among organic polymers can be used: dextran, polyglucin, starch, polyvinylpyrrolidone. The biopreparation can be dried by lyophilization, granulated and placed in polymeric matrix. The biopreparation has no toxic properties on animals, it shows good hygroscopicity and can be good dispersed in water. The biopreparation can be used in liquid and dry prescription formulations and in different methods of its administrations: both by subcutaneous, intraperitoneal, intramuscular injections and as an aerosol, by administration of phage particles into lung compartments including applying as curative fodder and supplement to fodder, and by applying on surface of cutaneous integuments. Invention provides enhancing the effectiveness of treatment of animals and poultries with gastroenteric infections due to reducing treatment period, expanding spectrum of lytic effect of the biopreparation, resistance to effect of digestive tract enzymes and convenience in using.

EFFECT: valuable veterinary properties of biopreparation.

9 cl, 5 tbl, 7 ex

The invention relates to the pharmaceutical industry and relates to the connection of a number of oxyindole, namely ethyl ester of 6-bromo-4-dimethylaminomethyl-1-methyl-5-hydroxy-2-phenylthio-methylindolin-3-carboxylic acid hydrochloride, which is an active substance of the drug Arbidol, and the drug based on it in the form of gelatin capsules

Capsule // 2240768
The invention relates to chemical-pharmaceutical industry, manufacturing of capsules, for example, for medication made of two films of water-soluble polymer material by deformation so as to form multiple cavities, and fill the cavity fluid filling material

The invention relates to pharmaceutical industry

FIELD: medicine.

SUBSTANCE: means has dibunol, 15% oil extraction of propolis, gelatin, glycerol and treated water taken in known component proportion.

EFFECT: enhanced effectiveness of treatment; prolonged regenerating and antibacterial action.

2 cl

Up!